Display options
Cite
Warthaka M, Adelmann CH, Kaoud TS, et al. Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Med Chem Lett. 2014;6(1):47-52doi: 10.1021/ml500198b.
Warthaka, M., Adelmann, C. H., Kaoud, T. S., Edupuganti, R., Yan, C., Johnson, W. H., Ferguson, S., Tavares, C. D., Pence, L. J., Anslyn, E. V., Ren, P., Tsai, K. Y., & Dalby, K. N. (2015). Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS medicinal chemistry letters, 6(1), 47-52. https://doi.org/10.1021/ml500198b
Warthaka, Mangalika, et al. "Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine." ACS medicinal chemistry letters vol. 6,1 (2015): 47-52. doi: https://doi.org/10.1021/ml500198b
Warthaka M, Adelmann CH, Kaoud TS, Edupuganti R, Yan C, Johnson WH, Ferguson S, Tavares CD, Pence LJ, Anslyn EV, Ren P, Tsai KY, Dalby KN. Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Med Chem Lett. 2014 Oct 17;6(1):47-52. doi: 10.1021/ml500198b. eCollection 2015 Jan 08. PMID: 25589929; PMCID: PMC4291693.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2014 Oct 17;6(1):47-52. doi: 10.1021/ml500198b. eCollection 2015 Jan 08.

Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine.

ACS medicinal chemistry letters

Mangalika Warthaka, Charles H Adelmann, Tamer S Kaoud, Ramakrishna Edupuganti, Chunli Yan, William H Johnson, Scarlett Ferguson, Clint D Tavares, Lindy J Pence, Eric V Anslyn, Pengyu Ren, Kenneth Y Tsai, Kevin N Dalby

Affiliations

  1. Division of Medicinal Chemistry, College of Pharmacy, Department of Biomedical Engineering, and Department of Chemistry, The University of Texas , Austin, Texas 78712, United States.
  2. Department of Immunology and Department of Dermatology, The University of Texas MD Anderson Cancer Center , Houston, Texas 77030, United States.
  3. Division of Medicinal Chemistry, College of Pharmacy, Department of Biomedical Engineering, and Department of Chemistry, The University of Texas , Austin, Texas 78712, United States ; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University , 61519 Minia, Egypt.
  4. Division of Medicinal Chemistry, College of Pharmacy, Department of Biomedical Engineering, and Department of Chemistry, The University of Texas , Austin, Texas 78712, United States ; Division of Medicinal Chemistry, College of Pharmacy, Department of Biomedical Engineering, and Department of Chemistry, The University of Texas , Austin, Texas 78712, United States.

PMID: 25589929 PMCID: PMC4291693 DOI: 10.1021/ml500198b

Abstract

Protein kinases are mutated or otherwise rendered constitutively active in numerous cancers where they are attractive therapeutic targets with well over a dozen kinase inhibitors now being used in therapy. While fluorescent sensors have capacity to measure changes in kinase activity, surprisingly they have not been utilized for biomarker studies. A first-generation peptide sensor for ERK based on the Sox fluorophore is described. This sensor called ERK-sensor-D1 possesses high activity toward ERK and more than 10-fold discrimination over other MAPKs. The sensor can rapidly quantify ERK activity in cell lysates and monitor ERK pathway engagement by BRAF and MEK inhibitors in cultured melanoma cell lines. The dynamic range of the sensor assay allows ERK activities that have potential for profound clinical consequences to be rapidly distinguished.

Keywords: ERK; biomarker; melanoma

References

  1. Clin Cancer Res. 2005 Jun 15;11(12):4338-40 - PubMed
  2. Adv Anat Pathol. 2013 Jul;20(4):217-26 - PubMed
  3. Biochemistry. 2011 May 10;50(18):3660-72 - PubMed
  4. Cancer Discov. 2012 Mar;2(3):227-35 - PubMed
  5. J Transl Med. 2013 Mar 08;11:61 - PubMed
  6. N Engl J Med. 2012 Feb 23;366(8):707-14 - PubMed
  7. Nature. 2010 Dec 16;468(7326):968-72 - PubMed
  8. Lancet Oncol. 2012 Nov;13(11):1087-95 - PubMed
  9. Bioorg Med Chem Lett. 1998 Oct 20;8(20):2839-44 - PubMed
  10. Nat Biotechnol. 2011 Nov 08;29(11):981-3 - PubMed
  11. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6 - PubMed
  12. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  13. PLoS One. 2011 Apr 11;6(4):e18594 - PubMed
  14. Chem Biol. 2012 Feb 24;19(2):210-7 - PubMed
  15. ACS Chem Biol. 2011 Jan 21;6(1):101-5 - PubMed
  16. Biochemistry. 2011 Nov 8;50(44):9500-10 - PubMed
  17. Nature. 2012 Jul 26;487(7408):505-9 - PubMed
  18. ACS Chem Biol. 2007 Oct 19;2(10):665-73 - PubMed
  19. Anal Biochem. 2006 May 15;352(2):198-207 - PubMed
  20. Br J Cancer. 2010 Jun 8;102(12):1724-30 - PubMed
  21. N Engl J Med. 2010 Aug 26;363(9):809-19 - PubMed
  22. Nat Commun. 2012 Mar 06;3:724 - PubMed
  23. Nature. 2012 Jul 26;487(7408):500-4 - PubMed
  24. Nature. 2010 Sep 30;467(7315):596-9 - PubMed
  25. J Clin Oncol. 2013 May 10;31(14 ):1767-74 - PubMed
  26. Nat Rev Drug Discov. 2012 Nov;11(11):873-86 - PubMed
  27. J Am Chem Soc. 2008 Sep 24;130(38):12821-7 - PubMed
  28. Br J Dermatol. 2011 Apr;164(4):776-84 - PubMed
  29. Nat Rev Drug Discov. 2011 Oct 31;10 (11):811-2 - PubMed
  30. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  31. Chem Biol. 2012 Jan 27;19(1):140-54 - PubMed
  32. Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix - PubMed
  33. Lancet. 2012 Jul 28;380(9839):358-65 - PubMed
  34. J Clin Oncol. 2012 Jul 10;30(20):2522-9 - PubMed
  35. Cancer Discov. 2013 Jul;3(7):742-50 - PubMed
  36. J Biol Chem. 2002 Apr 12;277(15):12532-40 - PubMed
  37. Chem Rev. 2001 Aug;101(8):2449-76 - PubMed
  38. Cancer Cell. 2010 Dec 14;18(6):683-95 - PubMed
  39. J Am Chem Soc. 2005 Aug 3;127(30):10494-5 - PubMed
  40. J Biol Chem. 2005 May 20;280(20):19472-9 - PubMed
  41. N Engl J Med. 2012 Nov;367 (18):1694-703 - PubMed
  42. Nature. 2010 Dec 16;468(7326):973-7 - PubMed

Publication Types